Other Hepatitis

This profile concerns unspecified viral hepatitis rather than a single etiologic agent, aligning with the provided designation “Other Hepatitis” and “Unspecified viral hepatitis” [disease]. The source set supports inclusion of multiple human hepatitis viruses within the broader syndrome of acute and chronic liver disease, while highlighting HCV and HEV as well-characterized examples ^[1][2]. More granular etiologic detail for the umbrella category is not yet available from the supplied sources ^[3][4][5].

The supplied material indicates that hepatitis E infection causes acute hepatitis, and that in immunocompetent patients its clinical manifestations and laboratory abnormalities cannot be distinguished from those caused by other hepatitis viruses ^[2]. HEV is also reported to be a major public health concern in immunocompromised patients because infection can become chronic ^[2]. In pregnancy, acute viral hepatitis may be associated with fulminant liver failure, and the available review reports that most fulminant cases described in the literature were linked to HEV ^[6]. For the broader category, source-backed detail on symptom timing, complication frequency, or typical severity pattern is not yet available ^[1][2][6].

The sources describe major outbreaks of acute hepatitis in developing countries for HEV, and note that attention has also increased in developed countries because of reported autochthonous infections ^[2]. HEV is described as a zoonotic cause of these infections, with reported cases mainly in men over 50 years of age ^[2]. A review of fulminant viral hepatitis in pregnancy reports that most literature cases were concentrated in the Indian subcontinent and some African areas, whereas the problem was described as very low or absent in other regions ^[6]. More specific surveillance burden for the umbrella diagnosis “other hepatitis” is not available from the supplied evidence ^[1][2][6].

For HEV, the source text explicitly identifies waterborne transmission through drinking water contaminated with feces ^[2]. The same source also characterizes HEV as zoonotic, indicating that non-human exposure ecology is relevant ^[2]. No further transmission detail for the broader “other hepatitis” category is supported in the supplied material ^[1][6][5].

The supplied sources identify several groups with increased relevance: immunocompromised patients, in whom HEV infection can become chronic ^[2]; pregnant women, in whom acute viral hepatitis may progress to fulminant liver failure ^[6]; and, for HEV, men over 50 years of age ^[2]. The review of fulminant hepatitis in pregnancy also notes a concentration of reported HEV-related cases in the Indian subcontinent and some African areas ^[6]. Beyond these source-supported groups, additional risk-group detail is not yet available ^[1][2][6].

Source-backed prevention detail is limited. For HCV, the supplied abstract notes the lack of a protective vaccine ^[1]. For HEV, several vaccines are reported to have proved safe and effective in clinical trials, but none had been approved for use in Europe at the time of the source, and no additional public-health control measures are explicitly detailed in the provided text ^[2].

In monitoring contexts, this category should be read conservatively as an unspecified viral hepatitis label rather than a single disease with a fixed epidemiologic pattern [disease]. The source set suggests that the category may encompass agents with very different patterns, including persistent infection without a protective vaccine for HCV and outbreak-associated waterborne disease for HEV ^[1][2]. Because the evidence base provided is limited to selected hepatitis viruses and scholarly metadata, source-backed detail specific to the umbrella surveillance category is not yet available ^[3][4][5].

1. 1 Park SH et al. Immune responses to HCV and other hepatitis viruses. Immunity. 2014 Jan 16. PMID: 24439265. doi: 10.1016/j.immuni.2013.12.010. PubMed: https://pubmed.ncbi.nlm.nih.gov/24439265/
2. 2 Abravanel F et al. Hepatitis E virus. Med Mal Infect. 2013 Jul. PMID: 23608595. doi: 10.1016/j.medmal.2013.03.005. PubMed: https://pubmed.ncbi.nlm.nih.gov/23608595/
3. 3 Other Hepatitis Viruses. Zakim and Boyer's Hepatology. 2006. doi: 10.1016/b978-1-4160-3258-8.50040-1. DOI: https://doi.org/10.1016/b978-1-4160-3258-8.50040-1
4. 4 DATABASES: The Other Hepatitis. Science. 2005. doi: 10.1126/science.309.5734.539d. DOI: https://doi.org/10.1126/science.309.5734.539d
5. 5 Hepatitis G and other viral hepatitis. Hepatology. 1995. doi: 10.1016/0270-9139(95)94108-8. DOI: https://doi.org/10.1016/0270-9139(95)94108-8
6. 6 Tosone G et al. Epidemiology and pathogenesis of fulminant viral hepatitis in pregnant women. Minerva Ginecol. 2018 Aug. PMID: 28994560. doi: 10.23736/S0026-4784.17.04107-7. PubMed: https://pubmed.ncbi.nlm.nih.gov/28994560/

ICD-10

B19

ICD-11

1E50.Y

Total cases

379K

Total deaths

140

Peak month

2011-03

Coverage

1 reporting countries · 2010-01-01 → 2026-05-01